^
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
doxorubicin hydrochloride Sensitive: A1 - Approval
|
doxorubicin hydrochloride Sensitive: A1 - Approval
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
ADX-2191 Sensitive: A1 - Approval
|
ADX-2191 Sensitive: A1 - Approval
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
regorafenib Sensitive: A2 - Guideline
|
regorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
IE Sensitive: A2 - Guideline
|
IE Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
gemcitabine + docetaxel + cyclophosphamide oral Sensitive: A2 - Guideline
|
gemcitabine + docetaxel + cyclophosphamide oral Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
cyclophosphamide oral + regorafenib Sensitive: A2 - Guideline
|
cyclophosphamide oral + regorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
sorafenib + cyclophosphamide oral Sensitive: A2 - Guideline
|
sorafenib + cyclophosphamide oral Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
carboplatin + cyclophosphamide oral + etoposide IV Sensitive: A2 - Guideline
|
carboplatin + cyclophosphamide oral + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
carboplatin + cyclophosphamide oral Sensitive: A2 - Guideline
|
carboplatin + cyclophosphamide oral Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
cyclophosphamide oral + etoposide IV Sensitive: A2 - Guideline
|
cyclophosphamide oral + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline
|
gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline
|
carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
carboplatin + ifosfamide Sensitive: A2 - Guideline
|
carboplatin + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
cisplatin + ifosfamide + methotrexate + SGN-15 Sensitive: A2 - Guideline
|
cisplatin + ifosfamide + methotrexate + SGN-15 Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
ifosfamide + etoposide oral + methotrexate Sensitive: A2 - Guideline
|
ifosfamide + etoposide oral + methotrexate Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
sorafenib + everolimus Sensitive: A2 - Guideline
|
sorafenib + everolimus Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
gemcitabine + docetaxel Sensitive: A2 - Guideline
|
gemcitabine + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
cyclophosphamide oral + topotecan Sensitive: A2 - Guideline
|
cyclophosphamide oral + topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
cabozantinib tablet Sensitive: A2 - Guideline
|
cabozantinib tablet Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
cisplatin + SGN-15 + methotrexate IV Sensitive: A2 - Guideline
|
cisplatin + SGN-15 + methotrexate IV Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
cisplatin + SGN-15 Sensitive: A2 - Guideline
|
cisplatin + SGN-15 Sensitive: A2 - Guideline
|
TMB-H
|
Osteosarcoma
|
TMB-H
|
Osteosarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Osteosarcoma
|
MSI-H/dMMR
|
Osteosarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
MAP Sensitive: A2 - Guideline
|
MAP Sensitive: A2 - Guideline
|
No biomarker
|
Osteosarcoma
|
No biomarker
|
Osteosarcoma
|
methotrexate Sensitive: A2 - Guideline
|
methotrexate Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Osteosarcoma
|
NTRK2 fusion
|
Osteosarcoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK1 fusion
|
Osteosarcoma
|
NTRK1 fusion
|
Osteosarcoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK3 fusion
|
Osteosarcoma
|
NTRK3 fusion
|
Osteosarcoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
ERCC1 K504Q
|
Osteosarcoma
|
ERCC1 K504Q
|
Osteosarcoma
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
XPC K939G
|
Osteosarcoma
|
XPC K939G
|
Osteosarcoma
|
cisplatin Sensitive: C3 – Early Trials
|
cisplatin Sensitive: C3 – Early Trials
|
ERCC2 K751G
|
Osteosarcoma
|
ERCC2 K751G
|
Osteosarcoma
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
ERCC1 N118N
|
Osteosarcoma
|
ERCC1 N118N
|
Osteosarcoma
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
ERCC2 D312N
|
Osteosarcoma
|
ERCC2 D312N
|
Osteosarcoma
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
ABCG2 overexpression
|
Osteosarcoma
|
ABCG2 overexpression
|
Osteosarcoma
|
MAP Resistant: C3 – Early Trials
|
MAP Resistant: C3 – Early Trials
|
PGP overexpression
|
Osteosarcoma
|
PGP overexpression
|
Osteosarcoma
|
ifosfamide + mifamurtide Sensitive: C3 – Early Trials
|
ifosfamide + mifamurtide Sensitive: C3 – Early Trials
|
TAF15-CHN1 translocation
|
Osteosarcoma
|
TAF15-CHN1 translocation
|
Osteosarcoma
|
SP2577 Sensitive: C3 – Early Trials
|
SP2577 Sensitive: C3 – Early Trials
|
KANK1-NTRK2 fusion
|
Osteosarcoma
|
KANK1-NTRK2 fusion
|
Osteosarcoma
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
CDK4 amplification
|
Osteosarcoma
|
CDK4 amplification
|
Osteosarcoma
|
palbociclib + lenvatinib Sensitive: C3 – Early Trials
|
palbociclib + lenvatinib Sensitive: C3 – Early Trials
|
EGFR overexpression
|
Osteosarcoma
|
EGFR overexpression
|
Osteosarcoma
|
gemcitabine Resistant: D – Preclinical
|
gemcitabine Resistant: D – Preclinical
|
IGF1R expression
|
Osteosarcoma
|
IGF1R expression
|
Osteosarcoma
|
IGF-1R inhibitor Sensitive: D – Preclinical
|
IGF-1R inhibitor Sensitive: D – Preclinical
|
RB1 positive
|
Osteosarcoma
|
RB1 positive
|
Osteosarcoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
KDM1A overexpression
|
Osteosarcoma
|
KDM1A overexpression
|
Osteosarcoma
|
SP2577 Sensitive: D – Preclinical
|
SP2577 Sensitive: D – Preclinical
|
MALAT1 overexpression
|
Osteosarcoma
|
MALAT1 overexpression
|
Osteosarcoma
|
doxorubicin hydrochloride Resistant: D – Preclinical
|
doxorubicin hydrochloride Resistant: D – Preclinical
|
